Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum

This article was originally published in The Pink Sheet Daily

Executive Summary

Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.

You may also be interested in...

Survey Says: Diabetes The Top Category Targeted For Managing Spend

Health plans are looking to curb diabetes drug spending, with the therapeutic area being called out as the number one or two category for managing drug spend in a survey of payers conducted by Leerink.

Express Scripts' 2016 Formulary Continues Exclusion Of Gilead’s Harvoni

The pharmacy benefit manager released its national preferred formulary for 2016. AbbVie’s Viekira Pak remains the preferred alternative for hepatitis C, while Harvoni remains blocked from coverage.

Novo Nordisk CEO: Outcomes-Based Contracts For Diabetes ‘Problematic’

In interview with “The Pink Sheet,” Lars Sorensen discusses the pricing and rebating environment for diabetes drugs and the company’s attitude toward exclusionary formularies.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts